Erasca, Inc.
Key Metrics
- Previous Close
- $14.58
- 52-Week Range
- $2.11 – $24.28
- Market Cap
- $5.16B
- P/E (TTM)
- —
- EPS (TTM)
- -0.95
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 12.73
- PEG Ratio
- —
- Return on Equity
- -78.25%
- Return on Assets
- -21.39%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 8.29
- Debt/Equity
- 0.12
- Total Debt
- $44.71M
- Free Cash Flow
- $-210.46M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $4.93B
Market Snapshot
About
Erasca, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes multiple precision oncology programs targeting specific genetic mutations common in various solid tumors, including lung, colorectal, and pancreatic cancers. Erasca's lead programs include ERAS-007, an oral ERK1/2 inhibitor, and naporafenib, a pan-RAF inhibitor being developed for RAS-mutant tumors. The company employs a precision medicine approach, developing therapies designed to target specific molecular alterations in cancer cells. Founded in 2018 and headquartered in San Diego, California, Erasca went public in 2021 through a merger with a special purpose acquisition company (SPAC).